Supplementary Tables – Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece

Supplementary Tables – Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece

Supplementary Table 1: Fist-line Therapy Characteristics, Discontinuation and Switch to 2L. Supplementary Table 2: T790M mutation testing among patients progressing on or discontinued from 1L EGFR-TKI and Treatment Options. Supplementary Table 3: Third-, Fourth- and Fifth-line treatments.

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Future Science Group, Figshare, Lampaki, Sofia, Mountzios, Giannis, Georgoulias, Vassilis, Rapti, Aggeliki, Xanthakis, Ioannis, Baka, Sofia, Mavroudis, Dimitrios, Samantas, Epaminondas, Athanasiadis, Elias, Zagouri, Flora, Charpidou, Andriani, Somarakis, Alvertos, Papista, Christina, Nikolaou, Aristeidis, Anastasopoulou, Eleftheria, Paparepa, Zoe, Syrigos, Konstantinos N
Format: Dataset
Sprache:eng
Schlagworte:
Cancer therapy (excl. chemotherapy and radiation therapy)
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Supplementary Table 1: Fist-line Therapy Characteristics, Discontinuation and Switch to 2L. Supplementary Table 2: T790M mutation testing among patients progressing on or discontinued from 1L EGFR-TKI and Treatment Options. Supplementary Table 3: Third-, Fourth- and Fifth-line treatments.
DOI:10.25402/fon.20438838